Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane in Autism Spectrum Disorder
NCT02909959Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2017
- Primary completion
- May 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sulforaphane in Autism Spectrum Disorder (ASD), sponsored by University of North Carolina at Chapel Hill. Started Mar 2017; status: completed.
02
Drugs
sulforaphane
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02909959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909959.